title: Current standing and frontiers of gene therapy for meningiomas.
abstract: Meningiomas are among the most common intracranial tumors. The treatment of choice for these lesions is complete resection, but in 50% of cases it is not achieved due to tumor location and/or surgical morbidities. Moreover, benign meningiomas have high recurrence rates of up to 32% in long-term follow-up. Molecular analyses have begun to uncover the genetics behind meningiomas, giving rise to potential genetics-based treatments, including gene therapy. The authors performed a literature review on the most relevant genes associated with meningiomas and both current and potential gene therapy strategies to treat these tumors. Wild-type NF2 gene insertion, oncolytic viruses, and transfer of silencing RNA have all shown promising results both in vitro and in mice. These strategies have decreased meningioma cell growth, proliferation, and angiogenesis. However, no clinical trial has been done to date. Future research and trials in gene insertion, selective inhibition of oncogenes, and the use of oncolytic viruses, among other potential treatment approaches, may shape the future of meningioma management.
authors.affiliation: Tecnológico de Monterrey School of Medicine and Health Sciences;
authors.forename: Rafael
authors.initials: R
authors.lastname: De La Garza-Ramos
authors.forename: Jessica V
authors.initials: JV
authors.lastname: Flores-Rodríguez
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Martínez-Gutiérrez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Ruiz-Valls
authors.forename: Enrique
authors.initials: E
authors.lastname: Caro-Osorio
mesh_terms: D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008577:Meningeal Neoplasms / Q000235:genetics / Q000628:therapy*; D008579:Meningioma / Q000235:genetics / Q000628:therapy*; D016518:Neurofibromatosis 2 / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics